Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Suzuki, A. Articles by Kaneko, S. Search for Related Content PubMed Citation Articles by Suzuki, A. Articles by Kaneko, S. Neurotransmitters Other Neuroleptics Genetics

Association of the TaqI A Polymorphism of the Dopamine D₂ Receptor Gene With Predisposition to Neuroleptic Malignant Syndrome

OBJECTIVE: The pathophysiology of neuroleptic malignant syndrome is mainly explained by a central hypodopaminergic state. The familial occurrence of neuroleptic malignant syndrome suggests the involvement of a genetic mechanism in the predisposition to the syndrome. Therefore, the authors examined the association between the TaqI A polymorphism of the dopamine D₂ receptor gene (DRD₂), which alters DRD₂ density and function, and the development of neuroleptic malignant syndrome. METHOD: The subjects were 15 psychiatric patients who had developed neuroleptic malignant syndrome (12 patients with schizophrenia and three with major depression) and 138 patients with schizophrenia who had never developed neuroleptic malignant syndrome. The TaqI A genotypes, A1 and A2 alleles, were determined by the polymerase chain reaction method. RESULTS: The frequency of the A1 allele was significantly higher in the patients who had developed neuroleptic malignant syndrome (56.8%) than in the patients who had not (35.1%). The proportion of the A1 carrier was significantly higher in the patients with neuroleptic malignant syndrome (14 [93.3%] of 15 patients) than in those without the syndrome (79 [57.2%] of 138 patients). CONCLUSIONS: These findings suggest that the TaqI A DRD₂ polymorphism is associated with the predisposition to neuroleptic malignant syndrome.

This article has been cited by other articles:

				M. C Borovicka, L. C Bond, and K. M Gaughan Ziprasidone- and Lithium-Induced Neuroleptic Malignant Syndrome Ann. Pharmacother., January 1, 2006; 40(1): 139 - 142. [Abstract] [Full Text] [PDF]

				S. R. White Acute Dystonic Reaction and the Neuroleptic Malignant Syndrome Journal of Pharmacy Practice, June 1, 2005; 18(3): 175 - 187. [Abstract] [PDF]

				R. Freedman Schizophrenia N. Engl. J. Med., October 30, 2003; 349(18): 1738 - 1749. [Full Text] [PDF]

				Allelic Predictors of Vulnerability to Neuroleptic Malignant Syndrome? Journal Watch Psychiatry, November 15, 2001; 2001(1115): 4 - 4. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us